home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
Post navigation
Previous Post
Previous
Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights
Next Post
Next
IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update